A procedure that uses heat generated by radio waves to treat Barrett’s esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress.
Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett’s esophagus.
The procedure uses a scope inserted through the mouth to destroy the abnormal tissue. The investigators reported their findings in the New England Journal of Medicine.
“Patients with Barrett’s esophagus can go on to develop esophageal cancer,” said Steven A. Edmundowicz, M.D., professor of medicine and lead investigator at the School of Medicine study site. “Cancer of the esophagus usually is deadly. Less than 15 percent of patients with esophageal adenocarcinoma survive for five years, and in those with advanced Barrett’s esophagus, the risk that the condition will advance to become cancer is about 6 percent per year.”
In Barrett’s esophagus, part of the lining of the esophagus is replaced with cells that resemble intestinal cells. As the condition progresses, these cells become increasingly disordered. Long-standing acid reflux disease is common in those who develop Barrett’s esophagus, which affects about 1 percent of adults in the United States.
A total of 127 patients at 19 sites took part in the study, which used endoscopes to diagnose the disease and then to deliver radiofrequency ablation to the abnormal lining of the esophagus. The technique heats the abnormal tissue to destroy it while leaving the deeper layers of the esophagus undamaged.
All patients in the study had the disordered, cellular growth called dysplasia associated with more advanced Barrett’s esophagus. Patients were classified as having either low-grade dysplasia or high-grade dysplasia. All patients received the antireflux medication esomeprazole (Nexium) to keep their reflux disease in check as much as possible.
Led by Nicholas J. Shaheen, M.D., associate professor of medicine and epidemiology at the University of North Carolina at Chapel Hill, the investigators at the various study sites randomly selected patients to either receive radiofrequency ablation or to undergo a sham procedure in which endoscopes were inserted through the mouth and the lining of the esophagus was examined, but no radio waves were delivered.
Two patients received the actual treatment for every one who got a sham procedure. Those who received the ablation treatment could get up to four treatments during the 12 months of the study.
In the patients who had the treatment, dysplasia disappeared in just over 90 percent of patients with low-grade disease and in more than 80 percent of those with high-grade disease compared with about 23 percent of the low-grade patients and 19 percent of the high-grade patients who had sham procedures rather than the ablation therapy. In 78 percent of treated patients, the dysplasia and the abnormal intestinal-type cells disappeared.
“During the 12-month study period, we detected fewer cancers in the ablation group than in the control group,” Edmundowicz said. “But because cancers occurred in only five study patients, the numbers are not as powerful regarding cancer as they are regarding eradication of Barrett’s esophagus.”
The risk of progressing from Barrett’s esophagus to esophageal cancer is approximately 1 percent for those with low-grade dysplasia and 6 percent for those with high-grade disease.
“From these short-term results, it appears we may have another useful tool in our treatment arsenal,” Edmundowicz said. “Additional follow-up will be necessary to demonstrate the true effectiveness of radiofrequency ablation in preventing esophageal cancer in patients with Barrett’s esophagus.”